SCHEMBL15550463

SCHEMBL15550463

CC1(C)Oc2ccc(Br)cc2[C@@]2(COC(N)=N2)C12COC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15549460 1.00 BACE1 (1.00) BACE1
SCHEMBL15589429 0.93 BACE1 (0.86) BACE1
SCHEMBL15589421 0.93 BACE1 (0.86) BACE1
SCHEMBL15548861 0.93 BACE1 (0.86) BACE1
SCHEMBL15589221 0.84 BACE1 (1.00) BACE1
SCHEMBL15588986 0.84 BACE1 (1.00) BACE1
SCHEMBL15588979 0.82 BACE1 (1.00) BACE1
SCHEMBL15589401 0.81 BACE1 (1.00) BACE1
SCHEMBL15589004 0.81 BACE1 (1.00) BACE1
SCHEMBL15818402 0.81 BACE1 (1.00) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242973-B2 Chromane compounds COMENTIS, INC. (US) 2016-01-26 US disclosed
US-9242973-B2 Chromane compounds COMENTIS, INC. (US) 2016-01-26 US disclosed
US-9242973-B2 Chromane compounds COMENTIS, INC. (US) 2016-01-26 US disclosed
US-20150225386-A1 CHROMANE COMPOUNDS COMENTIS, INC. 2015-08-13 US disclosed
EP-2854797-A2 CHROMANE COMPOUNDS Comentis, Inc. (US) 2015-04-08 EP disclosed
US-8975415-B2 Chromane compounds COMENTIS, INC. (US) 2015-03-10 US disclosed
US-8975415-B2 Chromane compounds COMENTIS, INC. (US) 2015-03-10 US disclosed
US-8975415-B2 Chromane compounds COMENTIS, INC. (US) 2015-03-10 US disclosed
US-20140179695-A1 CHROMANE COMPOUNDS COMENTIS, INC. (US) 2014-06-26 US disclosed
US-20140179695-A1 CHROMANE COMPOUNDS COMENTIS, INC. (US) 2014-06-26 US disclosed
US-20140179695-A1 CHROMANE COMPOUNDS COMENTIS, INC. (US) 2014-06-26 US disclosed
WO-2013181202-A2 CHROMANE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2013-12-05 WO disclosed
WO-2013181202-A2 CHROMANE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179695-A1 CHROMANE COMPOUNDS BACE1, BACE2, APP BACE1 1/4885
US-20150225386-A1 CHROMANE COMPOUNDS BACE1, BACE2, APP BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.